Clinical trial · Observational
PD-1/PD-L1 Inhibitors and Anti-angiogenic Therapy Combined With/Without TACE/HAIC in Patients With BCLC B/C Hepatocellular Carcinoma Beyond Up-to-7
A Retrospective Study Comparing Interventional Therapy (TACE/HAIC) Combined With PD-1/PD-L1 Inhibitors and Anti-angiogenic Agents Versus PD-1/PD-L1 Inhibitors and Anti-angiogenic Agents Alone in the First-line Treatment of Intermediate and Advanced Hepatocellular Carcinoma Beyond up to Seven
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a retrospective study that retrospectively included patients with intermediate and advanced HCC beyond up to seven who received first-line treatment with PD-1/PD-L1 inhibitors and anti-angiogenic agents combined with/without TACE/HAIC from January 01, 2019 to December 31, 2023 in the Department of Hepatic Oncology and Department of Liver Cancer Surgery, Zhongshan Hospital, Fudan University.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PD-1/PD-L1 inhibits and anti-angiogenic agents | Drug | — | UNRESOLVED |
| TACE/HAIC | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Group LS
- description
- Logical therapy combined with systemic therapy
- interventionNames
- Procedure: TACE/HAIC
- Drug: PD-1/PD-L1 inhibits and anti-angiogenic agents
- label
- Group S
- description
- Systemic therapy alone（PD-1/PD-L1 inhibits and anti-angiogenic agents）
- interventionNames
- Drug: PD-1/PD-L1 inhibits and anti-angiogenic agents
Primary outcomes (2)
- measure
- PFS
- timeFrame
- Up to 48 months
- description
- The time from the beginning of treatment to the time of tumor progression or death from any cause (according to mRECIST and RECIST v1.1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who have been diagnosed with advanced hepatocarcinoma (HCC), confirmed histologically or clinically. * Patients with Barcelona (BCLC) stage B and C beyond up to seven; * Have not received any prior systemic therapy for HCC (including: chemotherapy, molecular targeted therapy, immunotherapy); * Receiving only post-marketing PD-1/PD-L1 inhibitors in combination with anti-angiogenic agents (including, but not limited to, drugs containing hepatocellular carcinoma indications); \*The interval between the first use of PD-1/PD-L 1 inhibitors and the use of anti-angiogenic drugs is ≤ 1 week * TACE was performed within 1 month prior/after the first PD-1/PD-L 1 inhibitor/antiangiogenic drug treatment; * TACE treatment followed by at least 1 cycle of combination therapy, including: cTACE and DEB-TACE; * There is at least 1 measurable lesion in the liver according to RECIST v1.1 criteria Exclusion Criteria: * Cholangiocellular carcinoma, mixed hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, or hepatic fibrous laminar carcinoma that has been pathologically/histologically confirmed; * Patients who do not meet the above definition of combination therapy; * Patients had malignant tumors other than HCC within 5 years prior to enrollment (except cured limited tumors, including cervical carcinoma in situ, basal cell carcinoma of the skin, and prostate carcinoma in situ)
References
Publications (0)
Data not yet available